/SCTL
SCTL Stock - Societal CDMO, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.10+0.92%
+$0.01 (+0.92%) • Apr 5
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SCTL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.09 – $1.11
TARGET (TP)$1.26
STOP LOSS$1.01
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.58
52W High$1.28
52W Low$0.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $94.64M | $90.21M | $75.36M | $66.50M | $99.22M |
| Gross Profit | $18.50M | $23.14M | $19.82M | $12.37M | $48.24M |
| Gross Margin | 19.5% | 25.6% | 26.3% | 18.6% | 48.6% |
| Operating Income | $-1,759,000 | $279,000 | $412,000 | $-8,342,000 | $23.63M |
| Net Income | $-13,274,000 | $-19,881,000 | $-26,504,000 | $-46,660,000 | $-38,436,000 |
| Net Margin | -14.0% | -22.0% | -35.2% | -70.2% | -38.7% |
| EPS | $-0.14 | $-0.34 | $-0.60 | $-1.97 | $-1.71 |
Company Overview
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SCTLBeat Rate
45%
Last 20 quarters
Avg Surprise
-30.7%
EPS vs Estimate
Beats / Misses
9/7
4 met exactly
Latest EPS
$-0.06
Q2 2024
EPS Surprise History
Q3 22
+25.0%
$-0.06vs$-0.08
Q4 22
0.0%
$-0.06vs$-0.06
Q1 23
+60.0%
$-0.02vs$-0.05
Q2 23
-20.0%
$-0.06vs$-0.05
Q3 23
-20.0%
$-0.04vs$-0.03
Q4 23
-150.0%
$-0.05vs$-0.02
Q1 24
0.0%
$-0.01vs$-0.01
Q2 24
-100.0%
$-0.06vs$-0.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 8, 2024 | $-0.03 | $-0.06 | -100.0% | ✗ MISS |
Q1 2024 | Mar 22, 2024 | $-0.01 | $-0.01 | 0.0% | = MET |
Q4 2023 | Nov 8, 2023 | $-0.02 | $-0.05 | -150.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.03 | $-0.04 | -20.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.05 | $-0.02 | +60.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2022 | Aug 10, 2022 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.08 | $-0.08 | 0.0% | = MET |
Q1 2022 | Mar 1, 2022 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $-0.11 | $0.03 | +127.3% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q1 2021 | Feb 26, 2021 | $-0.22 | $-0.48 | -118.2% | ✗ MISS |
Q4 2020 | Nov 9, 2020 | $-0.20 | $-0.09 | +55.0% | ✓ BEAT |
Q3 2020 | Aug 10, 2020 | $-0.16 | $-0.25 | -56.3% | ✗ MISS |
Q2 2020 | May 11, 2020 | $-0.03 | $-0.33 | -890.1% | ✗ MISS |
Q1 2020 | Mar 4, 2020 | $-0.25 | $0.61 | +344.0% | ✓ BEAT |
Q4 2019 | Nov 8, 2019 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-0.42 | $-0.13 | +69.0% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about SCTL
What is SCTL's current stock price?
Societal CDMO, Inc. (SCTL) is currently trading at $1.10 per share. The stock has moved +0.92% today.
What is the analyst price target for SCTL?
No analyst price targets are currently available for this stock.
What sector is Societal CDMO, Inc. in?
Societal CDMO, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is SCTL's market cap?
Societal CDMO, Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does SCTL pay dividends?
No, Societal CDMO, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAUGX
Augmedix, Inc.
$2.35
Mkt Cap: $0.1B
CYT
Cyteir Therapeutics, Inc.
$3.02
Mkt Cap: $0.1B
DBTX
Decibel Therapeutics, Inc.
$4.91
Mkt Cap: $0.1B
GRAY
Graybug Vision, Inc.
$5.50
Mkt Cap: $0.1B
OPNT
Opiant Pharmaceuticals, Inc.
$20.65
Mkt Cap: $0.1B
OPTN
OptiNose, Inc.
$9.60
Mkt Cap: $0.1B
PROC
Procaps Group S.A.
$1.01
Mkt Cap: $0.1B
SESN
Sesen Bio, Inc.
$0.63
Mkt Cap: $0.1B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
ZOM
Zomedica Corp.
$0.10
Mkt Cap: $0.1B
Explore stocks similar to SCTL for comparison